Exagen Inc. (NASDAQ:XGN) Receives $9.00 Consensus PT from Brokerages

Shares of Exagen Inc. (NASDAQ:XGN) have been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $9.00.

XGN has been the topic of a number of analyst reports. Roth Capital assumed coverage on Exagen in a report on Wednesday, June 24th. They issued a “buy” rating and a $8.00 price target on the stock. Wall Street Zen upgraded Exagen from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Canaccord Genuity Group dropped their price objective on Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Weiss Ratings lowered Exagen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. Finally, BTIG Research reduced their target price on shares of Exagen from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, May 12th.

Exagen Stock Performance

Shares of XGN stock opened at $6.45 on Friday. The firm has a market cap of $155.83 million, a price-to-earnings ratio of -7.25 and a beta of 2.05. Exagen has a 52-week low of $2.59 and a 52-week high of $12.23. The company has a quick ratio of 3.47, a current ratio of 3.47 and a debt-to-equity ratio of 1.67. The company’s 50 day moving average is $4.61 and its 200 day moving average is $3.84.

Exagen (NASDAQ:XGN) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $19.94 million during the quarter, compared to analyst estimates of $17.80 million. Exagen had a negative return on equity of 94.37% and a negative net margin of 29.49%. On average, sell-side analysts anticipate that Exagen will post -0.71 EPS for the current fiscal year.

Key Stories Impacting Exagen

Here are the key news stories impacting Exagen this week:

• Positive Sentiment: Revenue and earnings beat expectations: Second-quarter revenue reached a record $19.9 million, up 16% year over year and above the $17.8 million analyst consensus. The adjusted loss of $0.13 per share was also narrower than the expected $0.19 loss. Exagen Inc. Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Improving operating performance: AVISE CTD test volume rose 11%, while trailing-twelve-month average selling price increased 4% to $446 per test. Adjusted EBITDA loss narrowed sharply to $0.1 million from $1.7 million a year earlier, and GAAP net loss improved to $3.2 million from $4.4 million. Exagen Reports Record Second-Quarter Revenue and Narrows Losses
• Positive Sentiment: Guidance raised: Exagen increased its 2026 revenue forecast to $72 million-$75 million from $70 million-$73 million, slightly above the $71.6 million consensus estimate. Management said the company is approaching sustainable profitability and cash generation. Exagen Reports Record Second-Quarter Revenue and Raises Full-Year Guidance
• Neutral Sentiment: Management highlighted clinical evidence supporting AVISE testing, including a review of more than 3,100 patients, and discussed investments in pipeline innovation and AI-enabled tools for rheumatology workflows. The earnings call provided additional context on the company’s path toward profitability. Exagen Q2 2026 Earnings Call Transcript
• Negative Sentiment: Exagen remains unprofitable, reporting a $3.2 million quarterly net loss, while cash declined to approximately $24.6 million from $32.2 million at the end of 2025. The company also carries significant borrowings and continues to face reimbursement and cash-collection risks.
• Negative Sentiment: Recent disclosed insider activity showed three open-market sales and no purchases over the past six months, which may temper investor enthusiasm.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Balyasny Asset Management L.P. raised its stake in shares of Exagen by 27.1% during the 4th quarter. Balyasny Asset Management L.P. now owns 919,187 shares of the company’s stock worth $5,589,000 after acquiring an additional 195,759 shares in the last quarter. Vanguard Group Inc. boosted its stake in Exagen by 7.7% in the third quarter. Vanguard Group Inc. now owns 733,824 shares of the company’s stock valued at $8,065,000 after acquiring an additional 52,205 shares in the last quarter. Invesco Ltd. acquired a new stake in Exagen in the third quarter valued at approximately $7,420,000. Kennedy Capital Management LLC boosted its stake in Exagen by 77.6% in the third quarter. Kennedy Capital Management LLC now owns 551,848 shares of the company’s stock valued at $6,065,000 after acquiring an additional 241,127 shares in the last quarter. Finally, Wexford Capital LP grew its holdings in Exagen by 6.9% in the third quarter. Wexford Capital LP now owns 444,927 shares of the company’s stock worth $4,890,000 after purchasing an additional 28,579 shares during the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.